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ABSTRACT 
The influenza viral ribonucleoprotein complexes (vRNPs) are responsible 
for viral RNA synthesis. Each vRNP is comprised of one vRNA segment, the viral 
RNA dependent RNA polymerase complex (RdRP), and multiple copies of 
nucleoprotein (NP). NP serves as scaffold in formation of vRNPs, but also 
regulates vRNP activity. The N-terminus of NP contains a nonconventional 
nuclear localization signal (NLS1) essential for initial vRNP nuclear import, but 
also interacts with host RNA helicases to enhance viral RNA replication in the 
nucleus. NP contains at least one additional NLS sequence, with bioinformatics 
revealing a third NLS in some NP proteins.  
Published yeast-two hybrid results indicate that the first 20 amino acids of 
NP can sufficiently bind with cellular protein UAP56. Suggesting the interaction of 
NP-UAP56 can be a major mechanism of how NP involve in viral replication. 
Thus, to examine the role of the N-terminus of NP aside from its vRNP nuclear 
localization activity N-terminal 20 amino acid deletion mutants with or without the 
addition of the conventional NLS from SV-40 T-antigen were constructed, termed 
del20NLS-NP and del20-NP. Nuclear localization of vRNPs with these constructs 
was assessed by GFP expression and western blotting. All these constructs 
exhibit nuclear localization, consistent with NLS1 being utilized for vRNP 
localization but not NP localization and vRNP formation in the nucleus. 
Furthermore, qPCR results demonstrated decreased vRNA synthesis activity, 
exacerbated as the vRNA template is lengthened in both plasmids, consistent 
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with a lack of interaction with host RNA helicases. Interestingly, del20-NP vRNP 
activity is less severe than del20NLS-NP, suggesting perturbations of the N-
terminus disrupt vRNP activity. To narrow down the region responsible for vRNA 
expression defect, del10-NP was constructed. GFP expression displayed similar 
activity between del10-NP and WT-NP with del20-NP showing a severe 
defection, suggesting NP amino acids 11-20 might be the major region 
responsible for the vRNA synthesis defect. However, sucrose density gradient 
results do not support the published interaction between NP and UAP56 in 293T 
cells. These results support the N-terminal region, potentially amino acids 11-20 
of NP, is playing the important role in efficient viral gene expression during virus 
replication especially as vRNA template lengthen, and that the NLS1 of NP is not 
essential for NP/vRNP nuclear localization in our reconstituted vRNP assay.  
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CHAPTER ONE 
BACKGROUND AND SIGNIFICANCE 
 
The Impact of Influenza 
Commonly known as the flu, Influenza is a contagious respiratory disease 
caused by influenza viruses which creates seasonal health issues and even 
several pandemics. According to the Center of disease control (CDC), seasonal 
flu-related hospitalizations since 2010 ranged from 140,000 to 710,000, while flu-
related deaths are estimated to have ranged from 12,000 to 56,000 in United 
States. Further, three times during the 20th century the world experienced 
Influenza pandemics: 1918 Spanish flu (H1N1), 1957 Asian Flu (H2N2), 1968 
Hong Kong Flu (H3N2); and already once in the 21st century in 2009 with the 
swine flu (novel H1N1) (CDC). Influenza pandemics cause much higher number 
of deaths than seasonal influenza, with the number of deaths of the 1918 
Spanish flu (H1N1) estimated to be at least 50 million worldwide with about 
675,000 occurring in the United States. The 1957 Asian flu caused around 1.5 to 
2 million worldwide and 70,000 deaths in the US, the 1968 Hong Kong flu 
resulted in 1 million worldwide and 34,000 deaths in the US, and the 2009 swine 
flu has reported with around 18,000 worldwide and 4,000 deaths in the US. All 
these pandemics were caused by Influenza virus type A. 
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There are several reasons why Influenza epidemics can be 
unmanageable and result in pandemics. First, the incubation period is extremely 
short (1-4 days). Second, virus particles are spread through droplets of sneezing 
or coughing easily, just one droplet can contain 100,000 to 1,000,000 virus 
particles. Next, since the initial flu symptoms are usually not severe, lots of 
infected individuals tend to continue their normal activities which help spread the 
virus. Influenza is spread by tiny droplets made when the virus carrier coughs, 
and can be passed on without the carrier even having any symptoms. Further, 
Influenza can be hard to diagnose without a laboratory exam as several diseases 
share the same symptoms. People with influenza infection can have symptoms 
such as fever, cough, sore throat, runny or stuffy nose, muscle or body aches, 
headaches, fatigue, and rarely some people will have vomiting and diarrhea 
(CDC). These symptoms are similar to the common cold, but the common cold is 
a much milder disease that can be caused by one of over 100 different types of 
rhinoviruses and is not lethal. Most patients can recover from influenza infection 
in several days to less than two weeks (CDC). However, to young children, 
elderly, and people who have immune deficiencies or disease (like AIDS), there 
is a higher chance for complications such as a secondary bacterial pneumonia 
which can result in death (WHO). 
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The Influenza A Virion 
Influenza virus is a member of the Orthomyxoviridae family. There are three 
types of influenza viruses that infect people, type A, type B, and type C (CDC). 
They are classified according to antigenic differences in their nucleoprotein (NP) 
and matrix protein (M1), which are major structural components of their virions. 
All of them can cause similar symptoms in human but not confer immunity to one 
another. Among these three types, Influenza A viruses are responsible for all 
known pandemics in 20th and are the focus of this research.  
Influenza A viruses can be further classified to different subtypes based on 
the antigen type of hemagglutinin (HA) and neuraminidase (NA). HA is a protein 
that mediates binding and entry of the viral genome into the target cell, while NA 
is involved in the release of progeny virions from infected cells (Suzuki Y., 2005). 
Both HA and NA occur as a variety of subtypes, presently there are 18 different 
known HA antigens and 11 different known NA antigens (CDC). The result is that 
there are many strains of influenza A virus, however, only H1, 2, and 3, and N1 
and 2 are commonly found in human (Lynch JP et al., 2007). This research 
utilizes the Udorn Influenza A H3N2 lab strain virus to investigate the role of the 
N-terminus of Influenza Nucleoprotein (NP) in viral replication. 
The core of the influenza A virion consists of structures called viral 
ribonucleoprotein complexes (vRNPs) which are responsible for viral 
transcription and replication. Each vRNP is comprised of one vRNA segment, the 
viral RNA dependent RNA polymerase complex (RdRP), and multiple copies of 
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nucleoprotein (NP). RdRP is the composed of three subunits, one acidic (PA) 
and two basic (PB1 and PB2) which transcribe and replicate viral RNA in the 
nucleus. The vRNPs are packaged with M1 (matrix protein) and further 
surrounded by a host-derived lipid bilayer envelope containing three 
transmembrane viral proteins: HA, NA, and M2, resulting in progeny virions 
budding from the plasma membrane of infected cells (Figure 1). Virions contain a 
distinct arrangement of the eight vRNPs required for functional virus (Oxford and 
Hockley., 1987; Noda et al., 2006). The HA and NA proteins are external and raft 
anchored on the surface. Four M2 proteins form an ion channel which is internal 
and loosely attach with lipid rafts. The M2 ion channel is required to alter 
endosome pH and facilitate fusion of the virion with the endosome (Nayak et al., 
2009). 
Influenza A viruses are enveloped, negative-sense, single-stranded, RNA 
viruses whose genome contains eight segments coding for at least 10 unique 
proteins. Some RNA segment encodes multiple proteins using different reading 
frame from same segment (Figure 2). The term negative-sense RNA implies that 
the RNA genome cannot be translated into protein directly, it must first be 
transcribed to positive-sense RNA before it can be translated into protein 
products. Influenza transcription occurs in the nucleus so that host-splicing 
machinery can be utilized. Other encoded well defined viral proteins include NS1, 
and NS2, (Nonstructural proteins, NS2 also known as NEP). Worth mentioning, 7 
more novel proteins: PB1-F2 (Chen et al., 2001), PB1-N40 (Wise HM et al., 
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2011), PA-X (Jagger BW et al., 2012), PA-N155, PA-N182 (Muramoto Y et al., 
2013), M42 (Shih SR et al., 1998), and NS3 (Selman M et al., 2012) were 
discovered over the past 20 years though they are less well characterized and 
may not be expressed in all viral genotypes. 
 
The Influenza A Virus Life Cycle 
The Attachment and Entry to the Host Cell 
 Influenza A viruses specifically target the ciliated columnar epithelial cells 
lining the sinuses and airways. It is believed that NA has ability to break down 
respiratory tract secretions, making access to respiratory cells easier (Bouvier 
and Palese., 2008). The virion attaches to N-acetylneuraminic acid (sialic-acid) 
containing receptors at the cell surface. Once attachment is complete, the virus-
receptor complex is formed and taken into cells via receptor-mediated 
endocytosis, and the virus enters the host cell in an endosome. The endosomal 
low pH environment induces a conformational change in HA, exposing a fusion 
peptide and triggering the fusion of the viral and endosomal membranes (Hunag 
Q et al., 2003). The acidic environment also allows the M2 ion channel to be 
opened, which leads to the release of vRNPs into the host cell’s cytoplasm (Pinto 
LH et al., 1992). Influenza viral transcription and replication occurs in the nucleus 
and Nuclear localization signals (NLSs) found on vRNP proteins bind to cellular 
nuclear import machinery to allow vRNP nuclear localization (Figure 3).  
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 HA forms spikes on the viral lipid membrane which interact with the host 
cell through sialic acid residues on the cell surface. There are two linkages are 
found between sialic acids and the carbohydrates they are bound to in 
glycoprotein, α2-3 and α2-6.  Different HA subtypes prefer different linkages. For 
example, influenza viruses from humans prefer the α2-6 linkages; because α2-6 
linkages are found frequently in the upper respiratory tract while α2-3 linkages 
are mostly at the lower respiratory tract, making these cells a more difficult target 
for infection. Conversely, avian influenza viruses prefer α2-3 linkages, and since 
these linkages are rare within a human’s upper respiratory tract, it is rare for 
humans to get infected with avian influenza. Swine are susceptible to viruses of 
human as well as avian as they have cells with both α2-3 and α2-6 linkages in 
the upper respiratory tract (Skehel JJ et al., 2000). This explains why swine is 
considered a mixing vessel for avian and human influenza viruses. An example 
of this is the 2009 triple reassortment novel H1N1 virus. 
Transcription of the Viral Genome 
 Viral transcription begins once the vRNP enter the nucleus. The viral 
RdRP interacts with active host RNA polymerase II to steal the 5’cap from 
nascent host pre-mRNAs and use this to prime viral transcription. The PB2 
subunit within the RdRP recognizes and binds the 5’ cap structure, and the PA 
subunit has endonuclease activity that cleaves the cellular mRNAs to obtain a 
cellular capped RNA fragment that used by the viral RdRP to prime viral 
transcription (Li ML et al., 2001) in a process is called cap-snatching. The 
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polyadenylation of the viral mRNAs occurs via a stuttering mechanism wherein 
the viral RdRP moves back and forth over a stretch of Uracil residues to form a 
poly-A tail. After obtaining a 5’ cap and poly-adenylation, the viral mRNAs 
visually look the same as host mRNAs (Figure 4).  
Splicing and Translation of Viral Protein 
Segments 2, 3, 7, and 8 of influenza virus can encode multiple proteins 
through both alternate splicing and alternate translation mechanisms (Figure 2). 
Splicing is an important process in Influenza life cycle. Each influenza virion 
contains 8 RNA segments and can encodes and that for 10 different proteins. 
Segment 7 encodes the matrix protein M1, ion channel proteins M2 and M42; 
segment 8 encodes the nonstructural protein NS1, nuclear export protein 
NS2(NEP), and NS3 by alternative mRNA splicing M2 and NEP and NS3 are 
spliced products and are usually found in a much lower amount compare with 
NS1 and M1 (Amorim MJ et al., 2006). Influenza virus uses the host cells’ 
splicing machinery to express these proteins (Engelhardt OG et al., 2006).  The 
virus not only hijack the cellular splicing machinery, it also inhibits the host cell 
from using its own splicing machinery for the processing of host cell mRNAs. 
Viral nucleoprotein (NP) is also reported to interact with UAP56 (Momose F et al., 
2006), which is a cellular splicing factor and a member of DEAD Box family of 
RNA helicases (Shen et al, 2007). However, when UAP56 is downregulated 
using siRNA, no change in ratio of spliced mRNAs to their respective intron 
containing mRNAs is observed (unpublished Newcomb lab; Nagata et al., 2008; 
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Read and Digard., 2010). Therefore, UAP56 and the reported UAP56-NP 
interaction does not appear to be involved in viral mRNA splicing.  
Influenza virus also employs alternate translation to make the most of its 
small genome. Segment 2 encodes the polymerase basic (PB) proteins PB1, 
PB1-F2, and PB1-N40 by using alternative translation initiation sites (Wise HM et 
al., 2011; Muramoto Y et al., 2013) and segment 3 encodes the polymerase 
acidic (PA) proteins PA and PA-X by a ribosomal frameshift (Jagger BW et al., 
2012), as well as two additional N-terminally truncated forms, PA-N155 and PA-
N182 (Muramoto Y et al., 2013), by using alternative translation initiation sites.  
Replication of Viral Genome 
 Influenza viral genome is made with negative sense RNA, for the genome 
to be replicated it needs to be converted into positive sense RNA first, which then 
serves as templates to produce genomic viral RNAs. Replication begins after the 
viral protein synthesis and accumulation of viral proteins. Replication does not 
require a primer, the RdRP initiates viral RNA synthesis de novo. The eight 
negative sense RNA segments are used to generate eight complimentary 
positive sense RNA (cRNA) which have a 5’ tri-phosphate end and no 3’ poly-A 
tail. The cRNAs is encapsulated by free NP and bound at the ends by viral 
polymerase proteins. The viral RdRP uses cRNA as template to make many 
vRNAs, which are also encapsulated by free NP and bound by the viral RdRP to 
form vRNPs. The new vRNPs are be used to either assemble new virions (Figure 
3) or used to amplify viral gene expression (Figure 4).  
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Virion Assembly and Release 
 Chromosomal Maintenance 1 (CRM1) is the major mammalian export 
protein that facilitates the transport of large marcromolecules (like RNA and 
protein) across the nuclear membrane to the cytoplasm. Influenza viral protein 
M1 binds with negative sense vRNPs and NEP, NEP then binds to CRM1 and 
forms a “daisy-chain” complex. Through this complex, the vRNPs are exported 
out of the nucleus (Figure 3). 
Once the vRNPs have left the nucleus, they start traveling to the cell 
membrane where assembly and budding occur. The final step of closing and 
budding off of the viral particle is triggered by an accumulation of vRNP bound 
M1 (Bouvier and Palese., 2008). For a virion to be infectious, it must contain all 8 
vRNA segments. Packaging signals near the ends of the virus RNAs ensure that 
only one copy of each genome segment is selected for a new virion. M1 interacts 
with viral membrane glycoproteins (HA and NA) to assemble virions. After 
budding a virion will attach to cell receptors through HA until NA destroys the 
receptors to release the new progeny virions from the plasma membrane (Figure 
3). Additionally, NA will remove sialic acid residues from the virions to prevent the 
new progeny virions to bind with each other and enhance infectivity (Bouvier and 
Palese., 2008).  
 
10 
 
Antigenic Variation 
One major reason Influenza is hard to control is the rapid genetic mutation 
rate resulting in genetic variation. The viruses are constantly changing in two 
different methods, antigenic drift and shift. Antigenic drift are small genetic 
changes which happen continually over time during influenza genome replication 
because of the lack of proofreading abilities of the viral RdRP. These mutations 
usually produce viruses that are closely related and share the same antigenic 
properties and immune systems which had been exposed to the similar virus can 
typically recognize it and respond. However, if these small genetic changes keep 
accumulating over time, the changes can eventually be great enough to cause 
antigenic difference. In this case, the body’s immune system will not be able to 
recognize those altered viruses. Influenza antigenic drift on HA and NA are the 
reason neutralizing antibodies targeting Influenza are HA and NA are subtype 
specific, the antigenic changes account for the different subtypes.   
Antigenic shift is an abrupt, major change in the influenza A viruses, 
resulting in an entirely new HA subtype and/or NA subtype being introduced into 
human population. When a cell is infected with two different influenza viruses, the 
RNAs of both viruses are copied in the nucleus. When new virus particles are 
assembled and budding, the 8 RNA segments from each virus may package in 
new combinations to form novel virus. This process is called genetic 
reassortment (Figure 5). One evolutionary important example of reassortment is 
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the exchange of RNA segments between mammalian and avian influenza viruses 
which can give rise to pandemic influenza.  
 
Treatments and Vaccination for Influenza 
The two main methods of controlling Influenza infection are vaccination 
and antiviral treatments. Vaccination can prevent Influenza infection by activation 
of individuals’ immune system to produce antibodies against specific NA/HA 
subtypes that are predicted to be in circulation during the year of certain areas. 
Immunization is usually achieved using inactive virus vaccine or, less commonly, 
live attenuated virus vaccine. Inactivated virus vaccines involve the 
subcutaneous injection of a killed or inactivated virus; live attenuated virus 
vaccines are live viruses that encode viral proteins altered to diminish their 
pathogenic abilities yet still elicit immune response and are given using a nose 
spray inoculation. Vaccine must be produced prior to the influenza viral season 
and is engineered to target predominant circulating strains. However, the high 
diversity of rapid evolution of Influenza A viral subtypes makes vaccination 
treatment difficult, underlining the importance of antivirals. However, influenza 
genes encoding resistance to existing antiviral treatments have been reported, 
highlighting the need for new classes of antivirals (for review, Davis et. al. 2014).  
The first class of antiviral treatments include amantadine and 
rimantandine, which inhibit the influenza M2 ion channel. Resistance to M2 ion-
12 
 
channel inhibitors can be acquired via a single amino acid substitution in the 
transmembrane region of the M2 protein (Holsinger et al, 1994). According to the 
Center of Disease Control, 100% of H3N2 influenza viruses circulating in 2009-
2010 and 99.8% of 2009 pandemic H1N1 were resistant to M2 inhibitors. These 
data indicate that M2 ion channel inhibitors are no longer efficacious. The current 
class of antivirals include zanamivir and oseltamivir, which inhibit activities of 
influenza neuraminidase. Neuraminidase is one of the viral proteins that can be 
found on the surface of influenza viruses that enables the virus to be released 
from the host cell. Still, multiple single-amino-acid changes in neuraminidase can 
result in resistance and emerge during treatment (Kiso et al, 2004). The 2009 
pandemic H1N1 contains resistance to neuraminidase inhibitors in addition to M2 
ion-channel inhibitors (van der Vries et al, 2011) and it is likely only a matter of 
time before resistance to neuraminidase inhibitors rises to the level of resistance 
to the M2 inhibitors. Still, there are a number of new NA inhibitors in 
development, including CS-8958 from Daiichi Sankyo Co, A-322278 from Abbott 
Laboratories, and Peramivir from BioCryst Pharmaceutical.  
Other Influenza antivirals in development include T-705, from Toyama 
Chemical, an oral RNA polymerase inhibitor; DAS181/Fludase from Nexibio, 
which incorporates a sialidase that removes sialic acids from mucosal 
membranes thereby preventing viral attachment via HA glycoprotein. Most of 
these Influenza inhibitors are either under phase II or III trail development 
(Yamashita et al., 2008; Baz M et al., 2008). Most exciting, a new antiviral 
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targeting the PA endonuclease cap-snatching activity was recently approved for 
use in Japan. While all these antiviral studies are promising, the fact that there is 
lack of novel effective influenza antiviral treatments, and that treatment use 
selects for resistance, indicates an urgent need to discover new molecular 
targets that can be exploited to produce novel antiviral therapies. In this study, I 
aim to exploit biochemical interactions important for successful viral RNA 
synthesis in order to contribute toward the goal of developing innovative 
treatments.  
 
Influenza A Nucleoprotein 
Influenza A virus contains 8 genomic segments, the gene segment 5 of 
influenza A virus encodes a 498 amino acids (aa) long protein called 
Nucleoprotein (NP) which is a multifunctional protein with critical roles during 
various stages of the viral life cycle. Phylogenetic analysis of virus strains 
isolated from different hosts reveals that the NP gene is relatively well conserved 
among influenza A, with a maximum amino acid difference of less than 11% 
(Shu et al., 1993). Given NPs conservation, NP may be less prone to tolerate 
mutation and evolve resistance, making NP interactions compelling antiviral 
targets (Davis AM et al., 2014).  
Nucleoprotein (NP), a 56kDa protein, is rich in arginine, glycine and serine 
residues and has a net positive charge at neutral pH. NP is modified by 
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phosphorylation (Privalsky and Penhoet, 1978). An electron microscope (EM) 
model of a recombinant influenza virus RNP revealed that the molecule has an 
elongated, curved, banana-like shape, perhaps comprising two domains (Martin-
Benito et al., 2001). The crystal structure of NP reveals a head and body domain 
with an RNA binding pocket (Ye). The primary function of NP protein is to 
encapsulate the viral genome and form homo-oligomers to maintain 
ribonucleoprotein complex (RNP) structure (Prokudina Kantorovich EN et al., 
1996). NP is more than a structural component of the vRNP and is essential for 
viral RNA replication, acting as a cofactor to coat the newly synthesized viral 
complementary RNA (Shapiro GI et al., 1988). However, NP also plays other 
important roles such as the importing of vRNP into nucleus, the exporting of 
vRNP back to cytoplasm, and finally preventing their reentry into nucleus (Palese 
P et al., 2007; Neumann G et al., 1997; Ozawa M et al., 2007; Elton D et al., 
2001).  
The nuclear import of NP is regulated by Nuclear localization signals (NLS), 
which are peptide signals that allow larger molecules such as protein and protein 
complexes to be actively transported into the nucleus. Influenza vRNPs are 
larger than 50kDa, so at least one component with a NLS is needed. It has been 
reported that all vRNP proteins (NP, PB1, PB2, and PA) contain at least one NLS 
(Cros et al., 2005, Bullido et al., 2000, Neuman et al., 1997, Wang et al., 1997, 
Akkina et al., 1987, Jones et al., 1986, Nieto et al., 1994). The N-terminus of NP 
contains a nonconventional nuclear localization signal (NLS1) located at amino 
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acids 3 through 13 (NLS1) essential for initial vRNP nuclear import. NP contains 
at least one additional NLS sequence which is a classical NLS (cNLS) located at 
amino acids 198 through 216 aa (NLS2) (Wu WW et al., 2007; Ozawa M et al., 
2007; Elton D et al., 2001; Cros et al., 2005). In addition, bioinformatics revealed 
a third NLS located between the two NLSs in some NP proteins (Krishna et al, 
2008). Although several studies have concluded NLS1 is essential for NP nuclear 
import (Cros et al, 2005; Wu and Panté, 2007), there is still debate regarding the 
relative importance of each NLS for NP nuclear localization (Ozawa et al, 2007).  
Influenza viral RNA replication has two steps, first cRNA is synthesized 
using vRNA and then the cRNA serves as template to produce more vRNA. Viral 
RNA replication leads to increased vRNA templates available for transcription, 
amplifying production of viral mRNAs. NP has an active role in viral replication 
activity as it is responsible for anti-termination at the polyA addition site during 
vRNA to cRNA replication (Beaton et al, 1986). NP and the RdRP stabilize 
nascent cRNA and vRNA replication products (Vreede et al, 2004), and although 
NP is not essential for RNA replication on short templates (Lee et al, 2002), NP is 
required for synthesis of template sized RNAs (Beaton et al, 1986), and NP and 
RdRP interaction enhances unprimed RNA synthesis in vitro (Newcomb et al, 
2009). Thus, aside from the role of coating the RNA template, NP is elaborately 
involved in promoting viral RNA replication and viral gene expression.  
 NP interacts with many of viral and host proteins at various times during 
infection. For example, NP interacts with factors to alter vRNP location. The 
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NLS1 of NP interacts with importin α for importing vRNP complex into the 
nucleus (Hutchinson EC and Fodor E, 2012) and NP interacts with CRM1 to 
export vRNPs into cytoplasm (Elton D et al., 2001). NP also interacts with factors 
to facilitate viral RNA expression. NP interaction with MCM serves as scaffold 
between nascent RNA chains and the viral polymerase (Kawaguchi A and 
Nagata K, 2007), while NP interaction with Tat-SF1 and UAP56 are thought to 
serve as a chaperone for NP (Naito T et al., 2007; Kawaguchi et al., 2011).  
UAP56 is a 48-kDa polypeptide cellular splicing factor belonging to the 
DEAD-box family of RNA dependent ATPases and RNA helicases (Shen et al, 
2007), and is involved in cellular mRNA remodeling during mRNA processing 
and nuclear export (Fleckner et al, 1997). Furthermore, UAP56 appears to be 
involved in most of the mRNAs nucleus export and their proper translocation in 
the cytoplasm (Meignin et al, 2008). UAP56 is proposed to function as a 
chaperone to promote free NP binding to nascent viral RNA replication products 
resulting in enhanced viral RNA synthesis (Kawaguchi et al., 2011). UAP56 can 
interact with NPs of avian and human influenza A viruses. However, NP may rely 
more heavily on one for viral RNA replication in the host cell. In our lab, we 
hypothesize the unique roles in influenza infection for this host factor as UAP56 
knockdown resulted in accumulation of dsRNAs (Wisskirchen et al., 2011). The 
N-terminus of NP not only contains the essential NLS1, but was also implicated 
in interaction with UAP56, demonstrated through yeast two-hybrid analysis with 
partial NP proteins, revealing amino acids 1-20 are sufficient for interaction with 
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UAP56 (Momose et al., 2001). This interaction is reported to promote free NP 
binding to nascent viral RNA replication products, resulting in enhanced viral 
RNA synthesis in vitro (Kawaguchi et al., 2011). In agreement with this, the N-
terminus of NP is required for viral ribonucleoprotein formation with long 
templates in vivo (Sanchez et al., 2014). 
In this research, my goal is to understand the role of N-terminus of NP in 
viral RNA synthesis aside from its role in nuclear localization as the first 20 amino 
acids have been reported binding with host factor UAP56 while the region is also 
overlapping with one of NP’s non-conventional NLS signal. 
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Figure 1. Influenza A Virion 
 
Roughly spherical, Influenza A virion consists of 8 vRNP segments, surrounded 
by a matrix of M1 proteins, and a host derived lipid bilayer envelope which 
contains three transmembrane proteins (M2, HA, and NA). 
 
Credit: Racaniello V (2009). Influenza Viral RNA synthesis. Virology Blog – About 
Viruses and Viral Disease.  
< http://www.virology.ws/2009/04/30/structure-of-influenza-virus/> 
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Figure 2. Some Influenza RNA Segments Encodes Multiple Proteins 
 
There are eight segments of viral RNA within the Influenza A virion. They are 
responsible to code for at least 10 unique viral protein. This figure contains an 
11th novel viral protein PB1-F2, which had been reported may has functions to kill 
host immune cells responding to influenza virus infection (Chen et al., 2001). In 
this image segment 2 undergoes frameshift during translation and segments 7 
and 8 undergo alternate splicing.  
 
Credit: Racaniello V (2009). Influenza Viral RNA synthesis. Virology Blog – About 
Viruses and Viral Disease. 
< http://www.virology.ws/2009/05/01/influenza-virus-rna-genome/> 
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Figure 3. Influenza A Life Cycle 
 
Influenza A virus binds to the host cell surface with HA and the virion is 
transported into the cell in an endocytic vesicle via receptor mediated 
endocytosis. The low pH in the endosome activates a conformational change in 
HA and opens the M2 ion channel, allowing the release of vRNPs into the 
cytoplasm. The vRNPs then enter the nucleus with the assist of NLSs. Viral 
transcription and replication occur in the nucleus. Newly replicated vRNPs travel 
back to the cytoplasm to initiate the virion assembly process. The vRNPs 
assemble with the viral glycoproteins at the cell membrane where the virions will 
assemble and bud.   
 
Credit: Samji T (2009). Influenza A: Understand the Viral Life Cycle. Yale J Biol 
Med. 82(4): 153-159 
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Figure 4. Influenza A Transcription and Replication 
 
Transcription results in a positive sense mRNA that has 5’ cap and host 
sequences and terminates early using stuttering to generate a poly A tail. During 
replication, the viral RNA polymerase generates a complementary RNA (cRNA) 
replication intermediate, which is a full-length complement of the vRNA that 
serves as a template for the synthesis of new copies of vRNA.  
 
Credit: Racaniello V (2009). Influenza Viral RNA synthesis. Virology Blog – About 
Viruses and Viral Disease.  
< http://www.virology.ws/2009/05/08/influenza-viral-rna-synthesis/ > 
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Figure 5. Reassortment of the Influenza Virus Genome 
 
When a cell is infected with two different influenza viruses, the RNAs of both 
viruses are copied in the nucleus. When new virus particles are assembled at the 
plasma membrane, each of the 8 RNA segments may originate from either 
infecting virus. The progeny that inherit RNAs from both parents are called 
reassortants. This process is illustrated in the diagram above, which shows a cell 
that is co-infected with two influenza viruses L and M. The infected cell produces 
both parental viruses as well as a reassortant R3 which inherits one RNA 
segment from strain L and the remainder from strain M. Many different 
combinations of reassortants are possible.  
 
Credit: Racaniello V (2009). Influenza Viral RNA synthesis. Virology Blog – About 
Viruses and Viral Disease.  
< http://www.virology.ws/2009/06/29/reassortment-of-the-influenza-virus-
genome/> 
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CHAPTER TWO 
LOCALIZATION OF N-TERMINAL NP MUTANTS 
 
Background 
Given NP contains at least two nuclear localization signals (NLSs), there 
is still debate regarding the relative importance of each for NP nuclear 
localization during viral infection (Cros et al., 2005; Wu and Panté, 2007; Ozawa 
et al., 2007). To understand the role of N-terminus of NP on Influenza viral 
replication I first set out to understand the role of the N-terminus on NP nuclear 
localization, since NLS1 is within the N-terminus.  
I used two different methods to analyze NP location, cellular fractionation 
and fluorescent microscopy. For both I constructed N-terminal 20 amino acid 
deletion mutants with or without the addition of the conventional NLS from SV-40 
T-antigen, termed del20NLS-NP and del20-NP. In addition, I also constructed a 
WT-NLS NP (WT means Wild type) to study the impact of the extra conventional 
NLS to NP’s localization activity (Figure 6). For cellular fractionation NP mutants 
were constructed with a C-terminal FLAG epitope, while for fluorescent 
microscopy the NP mutants were fused at the C-terminus to GFP. 
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Results 
For cellular fractionation, NP mutants were transfected into 293T Human 
embryonic kidney cells. At ~48 hours post transfection proteins of cytoplasmic 
and nuclear fractions were isolated separated by SDS-PAGE gel and probed 
using western blotting technique to assess NP and mutant NP protein expression 
and location. Anti-FLAG antibody detects the C-terminal epitope tag of both WT 
NP and NP mutants. Anti-Hsp90 was used to detect Hsp90, which is a protein 
located in the cytoplasm and demonstrates only slight contamination into the 
nuclear fraction and uniform protein loading. The anti-Flag antibody confirmed 
that all the mutants: WTNLS-NP, del20-NP, and del20NLS-NP were present in 
both the nucleus and cytoplasm, similar as WT-NP (Figure 8). While we find that 
del20-NP and del20NLS-NP demonstrate relatively weaker protein expression 
compare with WT-NP and WTNLS-NP, there is significant NP expression in all 
mutants to characterize NP function in reconstituted vRNPs (Davis et al., 2017). 
For fluorescent microscopy, NP and NP mutant fusion with GFP allow 
visualization of NP location in the host cells. The plasmids constructed and used 
here were named WT-NP-GFP, WT-NLS-NP-GFP, del20NP-GFP, and del20-
NLS-NP-GFP. Plasmids were transfected into A549 human lung 
adenocarcinoma epithelial cells. SouthernBiotechTM DAPI-Fluoromount-GTM 
Clear Mounting Media was used to stain the cell nucleus. The GFP/protein and 
DAPI/nucleus were then observed using a EVOSTM FL fluorescent microscope to 
access NP and NP mutant localization. Plasmid eGFP alone was also 
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transfected to monitor transfection efficiency and eGFP location. At 48 hours’ 
post transfection, the cells were fixed with formaldehyde and the nucleus stained 
with DAPI mounting media. The fusion proteins were observed through 
fluorescence microscopy. The result is consistent with cellular fractionation in 
that all the NP mutants are expressed inside the nucleus (Figure 9). Interestingly, 
from the fluorescence microscopy image, we see punctate nuclear staining in all 
samples containing an N-terminal NLS, either from SV40 or NLS1 of NP. 
Punctate staining is less visible with the del20-NP-GFP; although the protein still 
expressed inside the nucleus, it is relatively spread out compared with other NP-
GFP fusion proteins (Figure 9). This may indicate that NLS1 or the additional 
NLS from the SV40-antigen could provide specific trafficking activity that can 
import and ‘accumulate’ the proteins in certain area of nucleus.  
In summary, cellular fractionation and fluorescence techniques (Figure 8 
and 14) were consistent and both indicate the N-terminal NP mutants with or 
without additional NLS from SV40 can all be found in the nucleus similar to WT-
NP. We conclude NLS1 is not essential for newly expressed NP nuclear 
localization and therefore the conventional NLS signal from SV40-antigen is not 
required for nuclear localization of NP in reconstituted vRNP assays 
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Figure 6. Nuclear Localization Signals (NLSs) on Nucleoprotein (NP) and NP 
Mutants Examined in this Study.  
 
The nuclear localization signal (NLS) is an amino acid sequence that 'tags' a 
protein for import into the cell nucleus. NP encodes at least two NLS peptides 
(Cros, 2005; Wu and Panté, 2007; Ozawa, 2007). The N-terminus of NP is also 
known to interact with host factors UAP56. del20-NLS-NP was constructed by 
Abel Sanchez, I then constructed del20-NP and WTNLS-NP. The additional NLS 
is a well-defined conventional NLS from SV-40 T-antigen.  
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Figure 7. Microscopy Confirms Broken Cytoplasm and Intact Nuclei after Addition 
of NP-40.  
 
293T expressing WT-NP, WTNLS-NP, del20NLS-NP, del20-NP were collected 
and fractionated with NP-40 non-ionic detergent to break open the cellular 
plasma membranes.  Nuclei were pellet, centrifuged, then subjected to sonication 
for protein isolation.   
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Figure 8. Mutant NPs are Expressed and Localized in the Nucleus and 
Cytoplasm Similar to WT-NP 
 
The protein extracts from both the cytoplasm and nucleus were separated on a 
10% SDS-PAGE gel, transferred to nitrocellulose, and analyzed by western blot 
technique with anti-FLAG and anti-Hsp90. Anti-FLAG antibody detects the C-
terminal epitope tag of all NP and NP mutant.  
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Figure 9. NP-GFP Fusion Proteins Demonstrate all NP Mutants are Located in 
the Nucleus 
 
WT-NP-GFP and NP mutant-GFP proteins or eGFP were expressed in A549 
cells grown on poly-L-Lysine coverslips. Cells were washed with Dulbecco's 
phosphate-buffered saline (DPBS) and fixed with 2% formaldehyde. The 
coverslips were mounted onto glass slides using Southern BiotechTM Dapi-
Fluoromount-GTM Clear Mounting Media which stains the cell nucleus (blue). The 
slides were then observed using EVOSTM FL fluorescent microscope and images 
were captured with associated camera software EVOSTM FL Color Imaging 
System for GFP (green) and DAPI (blue).  
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CHAPTER THREE 
ROLE OF INFLUENZA A NP N-TERMINUS IN VIRAL RNA SYNTHESIS 
 
Background 
The N-terminal 20 amino acids of NP is sufficient to bind host factor 
UAP56 (Momose et al., 2001), an RNA helicase (Shen et al, 2007) that functions 
as a chaperone of NP to enhance viral RNA synthesis (Momose et al, 2001; 
Kawaguchi et al, 2011). Further, losing the N-terminus of NP (amino acid 1-20) 
leads to decreased viral RNA synthesis, exacerbated by template length 
(Sanchez et al, 2014). Therefore, the identification of the importance of the N-
terminus of NP and its role has potential to reveal new antiviral targets within NP 
and interacting factors. 
Western blotting and NP-GFP fusion protein techniques have 
demonstrated that NLS1 is not required for newly made NP nuclear localization 
(Chapter 2). Thus, to examine the role of the N-terminus of NP in viral RNA 
synthesis, in addition to the mutants WTNLS-NP, del20NLS-NP, and del20-NP I 
also constructed an N-terminal 10 amino acid deletion mutant, termed del10-NP 
to further narrow down the region of NP responsible for the defect in expression 
from long templates (Sanchez et al., 2014). Del20-NLS-NP was used to serve as 
a comparison as we already knew this mutant had a severe defect. WTNLSNP, 
was also used to study the impact of altering the N-terminus with an additional 
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NLS signal on the activity of NP in viral RNA synthesis. These NP mutants were 
analyzed using reconstituted vRNPs.  
The reconstituted vRNP assay is a transfection-based system which 
exploits components of the reverse genetics procedure (Neumann et al, 1999) 
without generating recombinant mutant viruses. Instead, the mammalian cells (in 
this research, 293T Human embryonic kidney cells) are transfected with plasmids 
to generate one type of vRNP or cRNP complexes by expressing influenza RdRP 
and NP proteins alongside vRNA or cRNA templates respectively (Figure 10). 
The vRNA template can be directly transcribed to mRNA by the influenza RdRP, 
while the cRNA template must first be replicated to vRNA for transcription to 
occur. Transcription is assessed indirectly by detection of the subsequently 
translated protein through immunoblot and directly by reverse transcription PCR. 
The reconstituted vRNP assay was set up with RdRP (PB1, PB2, and PA), the 
vRNA template as either Flag-M vRNA or GFP-M vRNA and WTNP, no NP, or 
NP mutants WT-NLS-NP, del20NLS-NP, del20-NP and del10-NP. Cells pellets 
were collected for either protein or RNA isolation. Western blot technique was 
used to analyze viral protein expression and Reverse-transcriptase (RT) with 
quantitative polymerase chain reaction (qPCR) were used to analyzed viral RNA 
expression. 
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Results 
To study the expression of vRNP, plasmids to express reconstituted vRNP 
with either a short template Flag-M vRNA (7 amino acid tag) or a long template 
GFP-M vRNA (238 amino acid tag) were transfected into 293t cells. The cells 
were collected 48 hours’ post-transfection and the total protein or RNA was 
isolated. Total protein was separated by SDS-PAGE and Western Blot with Anti-
Flag to detect the viral NP and M-FLAG expression. Anti-tubulin was used as a 
loading control. The result show the N-terminus of NP is not essential for FLAG-
M expression in reconstituted vRNPs as the del20-NP and del20NLS-NP both 
show some viral protein (M) expression but is essential for longer GFP-M 
expression (Figure 11 and 12). Interestingly, addition of SV-40 NLS at the N-
terminus results in a more severe defect than del20 alone, especially for the long 
vRNA template (GFP-M vRNA) (Figure 12). These results indicate the N-
terminus of NP is important for gene expression from long templates and deletion 
of the N-terminal 20 amino acids and/or perturbation of the N-terminus results in 
severe gene expression defect with long templates. This is consistent with the 
fact that encoding a FLAG tag at the N-terminus of NP results in a non-functional 
vRNPs, hence why our NP proteins contain a C-terminal tag (unpublished data 
from Fady Boutros, Newcomb lab).  
To directly assess the mRNA synthesis activity of NP and NP mutants, 
total RNA was also analyzed. RNA was separated on a 1% agarose bleach gel to 
check integrity and confirm RNA concentration consistency by analysis of rRNA 
33 
 
(Figure 13). The samples were then treated with DNase and reverse-transcribed 
(RT) using oligo dT to obtain cDNA of all polyadenylated RNAs, including viral 
mRNAs, which then were analyzed using M specific primers and qPCR. qPCR 
with primers that targeted PA expression is used to normalize expression as PA 
is the limiting factor for vRNP expression during transfection. The results show M 
RNA expression is decreased in all mutants tested and with both templates 
indicating all NP mutants exhibit a severe defect in viral gene synthesis (Figure 
14). Consistent with the indirect protein results, the RNA defect was more severe 
with the GFP-M template, although a significant defect was observed with the 
FLAG-M template as well, even with del20NP, which showed only slight M 
protein defect in Western analysis (Figure 11). Duplicate trials with Flag-M vRNA 
template and analysis by relative qPCR demonstrate 32% and 23% activity with 
WT-NLS-NP, 15% and 7% with del20-NP, and 1.7% and 2% with del20-NLS-NP, 
compared to WT-NP set at 100% (Figure 14). With GFP-M vRNA template (one 
trial) a more severe defect is seen, at only 2.6 % expression with WTNLS-NP, 
0.8% with del20NP, and 1.6% with del20NLS-NP (Figure 14).  There is less 
activity with the longer template (GFP-M vRNA) than the shorter template (Flag-
M vRNA), consistent with the report of del20NLS-NP defect exacerbated by 
increasing vRNA template length (Sanchez et al., 2014). Our results reveal that 
addition of the NLS at the N-terminus contributes to the defect, comparing WT-
NP with WTNLS-NP (100% vs 32% and 23% with FLAG-M template and 2.6% 
with GFP-M template). We conclude the N-terminus of NP (amino acid 1-20) 
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plays an important role in viral RNA expression and deletion or perturbation will 
inhibit viral gene expression.  
 To narrow down the amino acids within the N-terminus of NP responsible 
for the defect of vRNA synthesis. Plasmid del10NP was constructed and 
analyzed for vRNP function by assessing GFP expression using the reconstituted 
vRNP system with vRNA template GFP-M. eGFP was used as a monitor for 
transfection efficiency. The result shows that del10-NP displayed similar activity 
as WT-NP with del20-NP showing more severe defection (Figure 15). This 
suggests the region important for robust vRNA synthesis is likely located within 
NP amino acids11-20. However, RNA analysis of these samples is underway to 
confirm no defect is observed at the RNA level.  
 In summary, reconstituted vRNP assay was used to assess N-terminal 
mutants for RNA expression activity indirectly with Western Blot and 
fluorescence microscopy, and directly by RT- qPCR. Our data indicate that the 
N-terminus of NP plays an important role in vRNA synthesis activity, because 
deletion of the N-terminal 20 amino acids or perturbation of the N-terminus by 
addition of amino acids results in a defective protein, particularly for RNA 
expression from long templates. Further probing of the N-terminus with a deletion 
of the N-terminal 10 amino acids suggest that the region responsible for the 
defect of vRNA expression is likely located within NP amino acid 11-20 (Figure 
15). 
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Figure 10. Reconstituted vRNP Expression System 
 
pcDNA expression vectors of PB1, PB2, PA, and NP or mutant are transfected 
into 293T cells to express protein components of the vRNP. A pHH21 expression 
vector encoding a genomic RNA template is also transfected (either vRNA or 
cRNA can be expressed). Cellular RNA polymerase I drives expression of the 
vRNA template from pHH21. Cellular RNA polymerase II drives expression of 
viral mRNAs from pcDNA3 encoding plasmids.  
 
Credit: Davis AM, Ramireez J, and Newcomb LL (2017). Identification of 
Influenza A nucleoprotein body domain residues essential for viral RNA 
expression expose antiviral target. Virol J. 14(1):22. Doi: 10. 1186/s12985-017-
0694-8 
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Figure 11. N-terminal NP Mutants are Expressed and Display Reduced vRNP 
Activity with FLAG-M vRNA Template. 
 
293T cells were transfected with plasmids to express reconstituted vRNPs 
containing vRNA-M templates with either the short 7 amino acid FLAG tag or the 
longer 238 amino acid GFP tag encoded at the N-terminus. All NP proteins are 
expressed fused to a C-terminal FLAG tag for ease of detection. Total protein 
extracts were isolated, separated by SDS-PAGE, and transferred to 
nitrocellulose. Anti-tubulin was used as a loading control. Anti-FLAG antibody 
was used to detect FLAG-M and NP-FLAG.  
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Figure 12. The N-terminus of NP is Essential for Full Reconstituted vRNP Activity 
from GFP-M Templates.  
 
Plasmids to express reconstituted vRNPs (Neumann, 1999) were transfected into 
293T cells, the vRNP complex containing influenza RdRP and GFP-M vRNA 
templates with either WTNP, WTNLSNP, del20-NP or del20NLS-NP. eGFP was 
transfected alone to monitor transfection efficiency. Cells were analyzed with the 
UV fluorescent microscopy and digital images were captured using Nikon 
Fluorescent inverted microscope and photo software. 
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Figure 13. RNA Separated on 1% Agarose Bleach Gel to Confirm Integrity and 
Equal Concentration of RNA Samples.  
 
Total RNA was isolated using Trizol according to the manufacturer’s protocol. 
RNA was quantified and evaluated for purity by taking OD260 and OD280 readings 
in duplicate on the NanoDrop ND1000 Nanospectrophotometer. RNA samples 
were then resolved on a 1% agarose bleach gel to observe RNA integrity by 
intact rRNA. Shown is a representative experiment with additional WT-NP and 
No NP RNA samples. 
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Figure 14. qPCR Data of M Expression of Duplicate Trails of Flag-M and Single 
Trail of GFP-M in WT-NP and NP Mutant Reconstituted vRNPs in 293T Cells. 
 
293T cells were transfected in triplicate with plasmids to express reconstituted 
vRNPs with either Flag-M vRNA or GFP-M vRNA template and WT-NP or NP 
mutants as indicated. RNA was isolated 48 hours’ post transfection. 1000ng of 
total RNA was treated with DNase before being reverse transcribed with oligo dT 
primer (mRNA) and analyzed through quantitative PCR with primers targeting the 
M gene. PA gene expression was used for normalization. Results were obtained 
from quadruplicate qPCR of duplicate trials of Flag-M vRNA and initial trail of 
GFP-M vRNA. Significances were evaluated through t-test by comparing with 
WT-NP; all samples showed p-values <0.0001. 
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Figure 15. The Del10NP Mutant Exhibits Similar GFP Expression to WTNP in 
Reconstituted vRNPs.   
 
Cells were transfected with plasmids to express reconstituted vRNPs with GFP-
M vRNA template and either WTNP, del20-NP or del10-NP. eGFP was 
transfected alone to monitor transfection efficiency. Cells were analyzed with the 
UV fluorescent microscopy and digital images were captured using Nikon 
Fluorescent inverted microscope and photo software. 
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CHAPTER FOUR 
NP N-TERMINUS INTERACTION WITH UAP56 HOST FACTOR 
 
Background 
The N-terminal 1-20 amino acids of NP is sufficient to bind host factor 
UAP56 using yeast two-hybrid assays (Momose et al, 2001).  The NP-UAP56 
interaction is reported to enhance viral RNA synthesis in vitro (Kawaguchi et al, 
2011). We have demonstrated the importance of the N-terminus of NP for viral 
ribonucleoprotein activity with long templates in vivo (Sanchez et al., 2013, 
current study), but have been unable to co-immunoprecipitate UAP56 with NP, 
even after cross-linking (data not shown, Sanchez et al). In the host cell, there 
are multiple DEAD box helicases with similarity to UAP56, including URH49, also 
found to interact with NP (Pryor et al, 2004). 
There are many methods that can be used to study protein-protein 
interaction, including co-immunoprecipitation, co-sedimentation in a gradient, 
yeast two-hybrid. Here, we use the density sucrose gradient approach in a small 
scale as a strategy to study WTNP-UAP56 interaction. The nucleoprotein has a 
Flag tag on its C-terminal for Western blot detection (WT-NP-flag). The density 
sucrose gradient exploits different sedimentation rates of complexes of differing 
molecular weight in a centrifugal force field to study protein interaction (Figure 
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16). Through their sedimentation behavior, we can infer if they interact with each 
other or not (Y Jin et al., 2013).  
Result 
To study NP-UAP56 interaction 293T cells were transfected with NP-
FLAG expressing plasmid. Total protein extracts were isolated 48 hours’ post-
transfection. Sucrose gradients were layered to create a gradient from 40%- 5% 
sucrose. After incubation at 4°C overnight the gradient is ready and the protein 
extract added to the top of the gradient (5%) and centrifuged for 16 hours at 
50,000 RPM in the ultracentrifuge at 4°C. 300ul Fractions were collected from the 
top of the gradient and analyzed with SDS-Page gel and Western blot.  
The result of sucrose density gradient approach shows NP located at 
fraction 8 and 9 while the UAP56 located at fraction 3-6. They have a significantly 
different in their sedimentation behavior (Figure 17). Interacting proteins should 
demonstrate distribution identical or overlapping distribution in the gradient 
centrifugation, while non-interacting proteins would not (Harlan et al., 2003). Our 
result, along with previous co-immunoprecipitation trials, indicates NP expressed 
alone in the 293T host cell has no interaction with UAP56. Therefore, we did not 
proceed with further efforts to prove the interaction and instead pursued 
characterization of additional N-terminal NP mutant del10NP. We conclude that 
while the N-terminus of NP is important for viral RNA elongation, consistent with 
a defect in the reported NP-UAP56 interaction, in 293T cells I was unable to 
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prove this interaction exists and cannot directly assess the N-terminal NP 
mutants.  
Another approach that we attempt to use for protein-protein interaction 
studying is the tripartite split-GFP system (Figure 18). Tripartite split-GFP is a 
novel micro-tagging system to monitor protein-protein interactions in vivo and in 
vitro. Its advantage is the small sizes of the GFP10 and GFP11 tagging peptides 
which makes it well suited to study interactions of unstable protein complexes 
that are difficult to detect with larger GFP tags (Cabantous et al, 2013; Figure 
18). We met obstacles while trying to construct the split-GFP plasmids as the 
plasmids couldn’t ligated during the construction, and while the sucrose gradient 
result came out suggesting negative interaction between NP alone with UAP56, 
we did not further pursue this approach, instead focusing on characterizing N-
terminus of NP in viral gene synthesis. 
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Figure 16. Sucrose Density Gradient 
 
A demonstration graph of the small scale of sucrose density gradient 
centrifugation for protein isolation. A gradient of sucrose solution is prepared. 
Total protein from 293T cells transfected to express WT-NP-FLAG are laid on top 
of the sucrose gradient. The tube is centrifuged at 4 oC for 16 hours. The solution 
is fractionated with equal volume into 10 fractions from the top to the bottom of 
the tube, the proteins within each fraction are analyzed by SDS-PAGE gel and 
Western blot. 
 
Credit: Modified from Y Jin, X. H. Cheng, F. Z. Yang, and L Fu (2013). 
Ultracentrifugation-based multi-target affinity selection mass spectrometry. RSC 
advance.  DOI: 10.1039 
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Figure 17. Sucrose Gradient Fraction of WT-NP Expressed Alone. 
 
10 gradient fractions were collected and analyzed using SDS-Page gel and 
Western blot technique. Anti-Flag was used to detect WT-NP-FLAG and anti-
UAP56 was used to detect the UAP56. Sucrose Gradient Fractionation reveal 
that WT-NP and UAP56 do not sediment together. This suggest that NP and 
UAP56 do not interact when NP is expressed in 293T cells. 
 
Credit: Jennifer Gallardo, Newcomb lab
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Figure 18. Tripartite Split-GFP System 
 
The system is based on tripartite association between two twenty amino-acids 
long GFP tags, GFP10 and GFP11, fused to interacting protein partners, and the 
complementary GFP1-9 detector. When proteins to which GFP10 and GFP11 
are fused to interact, GFP10 and GFP11 self-associate and recruit GFP1-9 to 
reconstitute a functional GFP, allowing visualization and study of the interaction 
between proteins (Cabantous et al, 2013). 
 
Credit: Cabantous S, Nguyen H, Pedelacq J, Koraichi F, Chaudhary A, et al. 
(2013). A new protein-protein interaction sensor based on tripartite split-gfp 
association. Scientific Reports, 3, 2854-2862. 
 
 
48 
 
CHAPTER FIVE 
MATERIAL AND METHODS 
 
Cells 
293T Human embryonic kidney and A549 human lung adenocarcinoma epithelial 
cell lines were purchased from ATCC (American tissue culture collection) and 
maintained in a water-jacketed incubator at 37°C with 5% CO2 output in DMEM 
(Dulbecco's Modified Eagle's Medium) with 10% FBS (Fetal bovine serum). Cells 
maintenance and passage are performed as manufacture’s protocol. 
 
Plasmids 
pcDNA plasmids WT-NP-FLAG, WT-NLS-NP-FLAG, del20-NLS-NP-
FLAG, del20-NP-FLAG, del10-NP-FLAG, PA, PB1, and PB2 were used to 
encode Influenza A/Udorn/307/72 (H3N2) mRNA to express PA, PB1, and PB2, 
NP viral proteins for vRNP expression. pHH21 GFP-M vRNAs and pHH21 Flag-
M vRNAs were used to express either GFP-M or Flag-M vRNP expression. The 
expressed GFP-M vRNA or Flag-M vRNA must be processed by viral 
polymerase ribonucleoprotein to be expressed as mRNA for translation to 
protein. WT-NP-GFP, WTNLS NP-GFP, del20NLS NP-GFP, and del20 NP-GFP 
were used for confirmation of viral protein localization. pcDNA plasmid 
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expressing PA, PB1, and PB2 were gifts from Krug lab. All other plasmids were 
generated in the Newcomb laboratory. PcDNA plasmids: WT-NP-Flag is 
constructed by Fady Boutros (Newcomb lab) and WT-NP-GFP is constructed by 
Alan Santana (Newcomb lab); pHH21 plasmids: Flag-M and GFP-M are 
constructed by Dr. Newcomb (Newcomb lab).  
For this study, I constructed WT-NLS-NP-FLAG, del20-NP-FLAG, and 
del10 NP-FLAG using one-step PCR with WT-NP-Flag as the template. In 
addition to proper restriction enzymes sites, WTNLS NP was constructed to 
encode the conventional NLS from SV40 T antigen (PKKKRKV) after the start 
codon (WT-NLS-NP) while the 3’ primer encoded the last amino acids of NP 
followed by a short glycine linker and the FLAG epitope tag (DYKDDDDK) prior 
to the stop codon. The del20-NP and del10-NP were constructed in a similar 
manner using the same 3’ primer but in this case the 5’ primer will encode the 
start codon followed by NP codon 21 or 11 (del20-NP, del10-NP, respectively). 
The PCR products were then digested with restriction enzymes EcoRI and XbaI 
and ligated into likewise cut pcDNA vector. All plasmids were sequenced at 
Retrogen (San Diego, USA) to confirm successful plasmid construction. 
I also constructed plasmids to express additional NP-GFP fusion proteins, 
WTNLS NP-GFP, del20NLS NP-GFP, and del20 NP-GFP, which were 
constructed by one-step PCR using the WT-NP-GFP as template. The 5’ primer 
either encoded the conventional NLS, between NP start codon and NP codon 1 
(WT-NLS-NP-GFP) or codon 21 (del20-NLS-NP-GFP) or encoding the start 
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codon followed by NP codon 21 (del-20-NP-GFP). The 3’ primer encoded the last 
amino acids of GFP and stop codon. PCR protocol is modified from the 
‘Molecular Cloning-A Laboratory Manual 3rd edition Vol2’ text book. 
 
PCR Primers 
Primers designed and used to generate the mutant NPs are as follow: (from 5’ to 
3’) 
WT-NLS-NP-F/ WT-NLS-NP-GFP-F: 
ATAGAATTCATGCCAAAGAAAAAGCGCAAGGTGGCGGCCGCGTCCCAAGG
C;  
del20-NP-F/ del20-NP-GFP F: 
ATGGAATTCATGCCAAAGAAAAAGCGCAAGGTGGCCGCGGAACAGATGGAA
ACTGATGGG;  
del20-NLS-NP-F/ del20NLS-NP-GFP-F: 
ATAGAATTCATGCCAAAGAAAAAGCGCAAGGTGGCGGCCGCGTCCCAAGG
C 
del10-NP-F:  
GCCGAATTCATGCAGATGGAAACTGATGGGGAACGCCAG;  
WTNLS-NP-R/ del20-NP-R/ del20-NLS-NP-R/ del10-NP-R: 
GACTCTAGATTAACCGTCATGGTCTTTGTAGTCCGCCGCATTGTCGTACTCC 
WTNLS NP-GFP-R/ del20 NP-GFP-R: 
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ATAGAATTCATGGCGTCCCAAGGCACC 
 
DNA Transfection 
293T cells or A549 cells were grown to 70% confluency in either 100mm 
or 6-well dishes. Plasmid DNA was purified using Qiagen QIAprep spin plasmid 
purification kit as per the manufacturer’s protocol. DNA with pcDNA plasmids to 
express either WT NP, WTNLS NP, del20NLS NP, del20 NP, del10 NP, and no 
NP control (pcDNA vector) alone or along with the appropriate additional pcDNA 
and pHH21 plasmids to express reconstituted vRNPs, were mixed with Mirus 
transfection reagent at a 1:3 ratio of DNA to reagent and cells are transfected as 
manufacturer’s protocol. eGFP was used to monitor transfection efficiency. At 
~48 hours post transfection cells are washed with 1X PBS, collected, and 
pelleted by centrifugation. 
 
Cellular Fractionation 
Cell pellets were resuspended in RSB (reticulocyte standard buffer, 10mM 
Tris HCl pH7.7, 10mM KCl, and 1.5mM MgCl2) and after incubation 0.2% NP-40 
is added to burst plasma membranes. Cells are examined under a microscope to 
confirm burst plasma membranes and intact nuclei. Homogenate is centrifuged 
300xg for 5 minutes at 4°C to yield a nuclear pellet and cytoplasmic supernatant. 
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The cytoplasmic fraction is collected and the nuclear pellet dissolved in Dignam 
buffer C (20mM HEPES pH7.9, 0.42M Nacl, 1.5mM Mgcl2, 0.2mM EDTA, no 
glycerol) to puncture the nuclear membrane and allow release of soluble factors. 
The nuclear fraction is then treated with Buffer E (20mM HEPES: KOH pH7.6, 
0.2mM EDTS, no salt) to reduce salt concentration. Both cytoplasmic and 
nuclear fractions are centrifuged at high speed to pellet cellular debris. The 
soluble fractions are then collected (protocol modified from Molecular Cloning A 
Laboratory Manual 3rd edition Vol1). 
 
Isolation of Total Protein 
For Western blot, cell pellets were resuspended in 10 volumes of the cell 
pellet in RIPA Lysis Buffer (25 mM HCl pH 7.6, 150 mM NaCl, 1% deoxycholate, 
0.1% SDS) with protease inhibitors. Lysed cells were subject to sonication to 
shear DNA using Fisher Scientific Sonic Dismembrator for 10 pulses at 30%, 
output 3-4.  
For sucrose gradient sedimentation, cell pellet was resuspended in RSB 
(reticulocyte standard buffer, 10mM Tris HCl pH7.7, 10mM KCl, and 1.5mM 
MgCl2) with 0.2% NP-40 and sonicated using Fisher Scientific Sonic 
Dismembrator for 10 pulses at 30%, output 3-4 to break nuclear membranes and 
shear genomic DNA. (protocol modified from Molecular Cloning A Laboratory 
Manual 3rd edition Vol1)   
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Isolation of Total RNA 
Total RNA was isolated using Trizol (Invitrogen) according to the 
manufacturer’s protocol. RNA was quantified and evaluated for purity by taking 
OD260 and OD280 readings in duplicate on the NanoDrop ND1000 
Nanospectrophotometer (Thermo Fisher Scientific). RNA was resolved on a 1% 
agarose bleach gel to observe RNA integrity and confirm RNA concentration.  
 
SDS-PAGE and Western Blot 
10% SDS-polyacrylamide gel was prepared to separate total protein 
extracts. Proteins were transferred to nitrocellulose using Fisher semi-dry 
transfer apparatus. Blots were incubated in primary antibody to recognize target 
and secondary antibody coupled to HRP. Pierce ECL reagents were used to 
detect HRP conjugated secondary antibody. Blots were developed using the 
Chemi-Hi setting on the ChemiDoc XRS (BioRad) System and digital images 
were obtained using Quantity One software (protocol modified from Molecular 
Cloning A Laboratory Manual 3rd edition Vol3 - Appendix). 
 
Antibodies 
Anti-FLAG antibody was purchased from Agilent, Anti-Hsp90 and anti-
Tubulin were purchased from Abcam, all antibodies were used at 1:1000 dilution 
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per manufacturer’s suggestion. Secondary HRP coupled anti-goat were 
purchased from Pierce and used at a 1:10,000 dilution as per manufacturer’s 
suggestion.  
 
Sucrose Density Gradient Centrifugation 
Sucrose gradients were made by layering of sucrose solutions prepared 
as 5%, 13.75%, 22.5%, 31.25%, and 40% sucrose. The sucrose layers were 
incubated overnight at 4oC to form a linear gradient. Total protein extract isolated 
using RSB and sonication was laid atop the gradient and centrifuged at 4oC for 
16 hours at 50,000 RPM. Ten fractions were collected and proteins resolved by 
SDS-PAGE and analyzed by Western blot (Protocol modified from The 
Laboratory of Andrew Murray at Harvard University).  
 
DAPI and GFP Visualization  
To assess NP localization, plasmids expressing NP-GFP or eGFP were 
transfected into A549 cells grown on poly-L-Lysine cover slips. 48 hours’ post 
transfection the cells were washed with 1XPBS 3 times for 5 minutes each and 
fixed with 2% formaldehyde for 20 mins at room temperature, and washed again 
with PBS (protocol modified from Dr. Thompson, CSUSB). Coverslips were 
mounted onto glass slides using SouthernBiotechTM DAPI-Fluoromount-GTM 
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Clear Mounting Media for 4 minutes, which stains the cell nucleus (protocol 
provided by SouthernBIotech). DAPI and GFP was observed in cells at 48 hours’ 
post-transfection on a EVOSTM FL fluorescent microscope and images were 
captured with associated camera software EVOSTM FL Color Imaging System.  
For reconstituted vRNP assays, the visualization of GFP-M fusions was 
done with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for fluorescence) 
inverted microscope and images captured with the Nikon DS-Qi1Mc camera with 
NS Elements software.  
 
Reverse Transcription  
Prior to reverse transcription RNA was first treated with RNase-free 
DNase (Promega) to degrade any contaminating plasmid DNA. 1 μg total RNA 
was subjected to reverse transcription using oligo dT and AMV reverse 
transcriptase. Promega reverse transcription system was used as per 
manufacturer’s protocol with the modification of increasing the reverse 
transcription time to 59 minutes to facilitate complete cDNA synthesis. Reverse 
transcription reactions were aliquoted from a master mix to ensure all samples 
received equivalent AMV-RT enzyme. 
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Quantitative PCR: Protocol and Primers 
Quantitative PCR (qPCR) reactions were run in the Applied Biosystems 
StepOnePlus Real Time PCR system using SYBR Green Master mix (Applied 
Biosystems), with ROX as the reference dye.  
Gene specific primers are as follow:  
M detection:  
(F) CGAGTATCATTGGGATCTTGCA, (R) TTCCTTTCGATATTCTTCCCTCATA  
PA detection:  
(F) GGACAAATGGAACATCAAAGATTAAA,  
(R) CAGAAGACTCGGCTTCAATCATG 
 
Statistical Analysis of qPCR Data 
Melt curve was confirmed to contain just one prominent peak above 72 oC 
before analyzing the qPCR data, to confirm specific PCR product amplification. 
Raw CT values were analyzed in Microsoft Excel using the ∆Ct/∆Ct formula of 
2^CTaverage control sample/2^CTaverage tested sample. Therefore, PA expression is used to 
normalization expression because PA is the limiting factor for vRNP expression 
during transfection. The ∆∆Ct formula is:  2^ ((CT average control sample) – (CT average 
housekeeping control)) – ((CT average tested sample) – (CT average housekeeping tested sample)). Error bars 
(standard error) were obtained by calculating the standard deviation of the 
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sample set divided by the square root of the sample set size. WT-NP samples 
were set at 100% and mutants analyzed by comparison to this reference.  
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CHAPTER SIX 
DISCUSSION AND FUTURE RESEARCH 
 
Discussion and Conclusion 
 The Nucleoprotein of Influenza A plays multiple critical roles within various 
stages of the Influenza viral life cycle. Pertinent to this project is the role of NP in 
viral RNA expression. Specifically, DEAD-Box RNA helicase UAP56 was 
identified in yeast-two hybrid assay to identify the interaction of host factors and 
NP. Yeast-two hybrid techniques were further employed to demonstrate sufficient 
binding between the first 20 amino acids of NP and DEAD-Box RNA helicase 
UAP56 (Momose et al., 2001). A cell-free system was then used to study the role 
of NP in viral replication and it was found that addition of UAP56 to the in vitro 
assay resulted in enhanced viral RNA synthesis (Kawaguchi et al., 2011).  
Consistent with these findings, an N-terminal deletion mutant, termed 
del20NLSNP validated the significance of the N-terminus of NP aside from vRNP 
and NP nuclear import by finding this N-terminal deletion with additional nuclear 
localization signal maintained nucleotide binding and nuclear localization but 
displayed diminished influenza RNA expression and vRNP formation, 
exacerbated by vRNA template length (Sanchez et al., 2014). These studies 
support further characterization of the importance of the N-terminus of NP and its 
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role in viral RNA expression to reveal new antiviral targets within NP and 
interacting factors.  
In NP nuclear localization study, our results demonstrated the additional 
NLS of NP is not essential for newly expressed NP nuclear localization in 
reconstituted vRNP assays (Figure 11). Further, we show addition of an NLS to 
the N-terminus of NP results in a more severe defect to vRNP activity as 
assessed by gene expression from the vRNA template. This result is consistent 
with an unpublished observation that encoding a FLAG tag at the N-terminus of 
NP results in non-functional vRNPs (unpublished data from Fady Boutros, 
Newcomb lab). To obtain a stable NP crystal for crystal structure analysis, the N-
terminus of NP had to be deleted (Ye Q et al., 2006), which suggests the N-
terminus of NP is a flexible region and might play an important role for NP 
function. Our results demonstrate adding amino acids to the N-terminus of NP 
results in inhibit of viral gene expression. 
Our data comparing two templates of varied length provide evidence that 
the N-terminus of NP is important for optimal gene expression especially as the 
vRNA template is lengthened. This data fit with the proposed role of UAP56-NP 
interaction to facilitate NP encapsidation of vRNA and cRNA templates, resulting 
in more templates for increased gene expression (Kawaguchi et al., 2011). While 
other groups have shown NP-UAP56 interaction, this was done either with yeast 
two-hybrid assay (Momose et al., 2001), in vitro purified proteins (Kawaguchi et 
al., 2011), or in cells using expressed FLAG-UAP56 (Wisskerchin et al., 2011). 
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All these approaches can result in false positives and are not representative of 
endogenous NP-UAP56 interaction. Unfortunately, our laboratory was unable to 
co-immunoprecipitate endogenous UAP56 with expressed NP-FLAG in 293T 
cells, even with cross-linking (Sanchez, Newcomb lab, data not shown) or 
demonstrate interaction using sedimentation on sucrose gradient (Figure 17). 
While a negative result on the sucrose gradient does not disprove interaction, the 
lack of interaction in cross-linking and co-IP together with the sucrose gradient 
are strong evidence these factors do not interact in the cell. However, given 
complexes can separate during sucrose gradient analysis, a control showing two 
proteins maintaining interaction through the sucrose gradient will help confirm the 
negative result. Indeed, we are able to demonstrate NP-PB2 interaction with this 
approach (data not shown). We conclude that in our hands, NP expressed alone 
in 293T cells do not show demonstrable interaction with UAP56 (Figure 17). We 
speculate another host factor, perhaps the UAP56 paralog URH49, interacts with 
the N-terminus of NP in the cell.  
In conclusion, the N-terminal NLS1 of NP is not essential for NP nuclear 
localization in our reconstituted vRNP assay. Addition of SV-40 NLS was shown 
not only to be unnecessary for proper NP localization, but also resulted in further 
defect to viral gene expression. Our results indicate modification of N-terminus of 
NP perturbs NP and inhibits gene expression, especially as template is 
lengthened. We speculate adding peptide sequence to the N-terminus disrupts 
an important N-terminal NP interaction. Interestingly, we narrowed the region 
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responsible for the phenotype observed with del20NP as possibly located within 
NP amino acids 11-20. This is based on an indirect approach using protein gene 
expression with del10NP vRNPs, which quantitatively appear to function as well 
as WTNP vRNPs. However, we have not elucidated the exact mechanism of the 
defect. Furthermore, we were unable to demonstrate interaction between WTNP 
and host factor UAP56, and therefore cannot assess interaction with our NP 
mutants. However, our data disputes existence of NP-UAP56 interaction and we 
hypothesize a different interaction is of importance, and that this interaction is 
disrupted with our N-terminus NP mutants. 
 
Future Direction 
Future studies will build off this work to narrow down and locate the 
specific amino acids responsible for the defect of viral gene expression observed 
with reconstituted vRNPs. The del10 reconstituted vRNP GFP expression 
suggest the region is located within NP amino acids 11-20 (Figure 15). However, 
direct RNA analysis is required for confirmation.  
Given multiple attempts to confirm the reports of NP-UAP56 interaction, 
future research will first determine if the paralog of UAP56, URH49, is the in vivo 
host factor interacting with the N-terminus of NP and relevant in our experiments.  
If not, the plasmids constructed for the tri-partite split GFP assay could be used 
with a cDNA library fused to GFPd11 to identify additional potential interacting 
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factors. Further, an N-terminal NP-GFPd10 could be constructed and used with a 
cDNA library fused to GFPd11 in the tri-partite split GFP assay to specifically 
select for proteins which interact with the N-terminus of NP.   
Lastly, I contributed to attempts to make a recombinant virus expressing 
NP-FLAG. I constructed a pHH21 plasmid to express the NP-FLAG coding 
sequence as a vRNA genome segment. For this construct a section of the coding 
sequence needed to be repeated to ensure NP-FLAG vRNA genome packaging 
in the new virions. Although our initial attempts to generate recombinant NP-
FLAG expressing virus was not successful, future research aims to generate this 
NP-FLAG virus to serve as a tool for studying NP host factor interaction during 
actual virus infection
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